311 related articles for article (PubMed ID: 31686407)
1. An Update on Vitamin D and Disease Activity in Multiple Sclerosis.
Smolders J; Torkildsen Ø; Camu W; Holmøy T
CNS Drugs; 2019 Dec; 33(12):1187-1199. PubMed ID: 31686407
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D
Smolders J; Mimpen M; Oechtering J; Damoiseaux J; van den Ouweland J; Hupperts R; Kuhle J
Acta Neurol Scand; 2020 Jan; 141(1):77-80. PubMed ID: 31657006
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of daily high-dose vitamin D
Hupperts R; Smolders J; Vieth R; Holmøy T; Marhardt K; Schluep M; Killestein J; Barkhof F; Beelke M; Grimaldi LME;
Neurology; 2019 Nov; 93(20):e1906-e1916. PubMed ID: 31594857
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D for the management of multiple sclerosis.
Jagannath VA; Filippini G; Di Pietrantonj C; Asokan GV; Robak EW; Whamond L; Robinson SA
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD008422. PubMed ID: 30246874
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
7. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).
Camu W; Lehert P; Pierrot-Deseilligny C; Hautecoeur P; Besserve A; Jean Deleglise AS; Payet M; Thouvenot E; Souberbielle JC
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454777
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
Røsjø E; Steffensen LH; Jørgensen L; Lindstrøm JC; Šaltytė Benth J; Michelsen AE; Aukrust P; Ueland T; Kampman MT; Torkildsen Ø; Holmøy T
J Neurol; 2015 Dec; 262(12):2713-21. PubMed ID: 26429571
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
11. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of vitamin D in relation to bone health.
Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D supplementation for sickle cell disease.
Soe HHK; Abas AB; Than NN; Ni H; Singh J; Said ARBM; Osunkwo I
Cochrane Database Syst Rev; 2020 May; 5(5):CD010858. PubMed ID: 32462740
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M;
J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.
Burton JM; Kimball S; Vieth R; Bar-Or A; Dosch HM; Cheung R; Gagne D; D'Souza C; Ursell M; O'Connor P
Neurology; 2010 Jun; 74(23):1852-9. PubMed ID: 20427749
[TBL] [Abstract][Full Text] [Related]
16. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.
Laursen JH; Søndergaard HB; Sørensen PS; Sellebjerg F; Oturai AB
Mult Scler Relat Disord; 2016 Nov; 10():169-173. PubMed ID: 27919484
[TBL] [Abstract][Full Text] [Related]
18. Immune regulatory effects of high dose vitamin D
Muris AH; Smolders J; Rolf L; Thewissen M; Hupperts R; Damoiseaux J;
J Neuroimmunol; 2016 Nov; 300():47-56. PubMed ID: 27806875
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]